NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
Clinical Trials
47 trialsNCT07394387 2026-02-06
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07331883 2026-01-21
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07351487 2026-01-20
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06121505 2025-12-17
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Sichuan University
Phase 2 Recruiting
NCT07263386 2025-12-04
ARTEMIS-GC3
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT06577194 2025-09-19
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06031285 2025-07-23
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06050317 2025-07-22
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07040098 2025-06-26
STELLARIII
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT06698757 2025-03-13
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05057052 2025-02-27
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
Phase 2 Recruiting
NCT05098847 2025-02-27
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
Fudan University
Phase 2 Recruiting
NCT06841159 2025-02-24
iPULSAR-CRC
Fudan University
Phase 2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06787911 2025-01-22
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT06204094 2025-01-07
CASINOs
Jinhua Central Hospital
Phase 2 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06558227 2024-12-16
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Recruiting
NCT03872661 2024-12-06
NIBCUN
Sun Yat-sen University
Phase 2 Recruiting
NCT06709417 2024-11-29
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06685276 2024-11-20
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06313190 2024-11-18
HSBRT2402
Sun Yat-sen University
Phase 2 Recruiting
NCT06664996 2024-10-30
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
West China Hospital
Phase 2 Recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06479759 2024-06-28
ACCLAIM
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06403878 2024-05-08
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Sichuan University
Phase 2 Recruiting
NCT06383559 2024-04-25
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05098119 2024-03-26
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05004974 2024-03-12
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Recruiting
NCT06240689 2024-02-05
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06220552 2024-01-24
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2 Recruiting
NCT06190639 2024-01-05
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT04589754 2024-01-02
Adriamycin and Ifosfamide Combined With Sintilimab
Sun Yat-sen University
Phase 2 Recruiting
NCT06091423 2023-11-30
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04728724 2023-09-13
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05757336 2023-03-07
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Fudan University
Phase 2 Recruiting
NCT05000892 2022-12-02
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting